AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Pulmonx Corporation
Video analysis: LUNG
All videosNo video analysis for this stock yet. Request one from our team.
News: LUNG
Deutsche Bank AG Takes Position in Pulmonx Corporation $LUNG
Deutsche Bank AG purchased a new stake in Pulmonx Corporation (NASDAQ: LUNG) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 402,316 shares of the company's stock, valued at approximately $523,000. Deutsche Bank AG owned approximately 0.94% of
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year
Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript
